Vittorio Bertelè

3.8k total citations
85 papers, 2.2k citations indexed

About

Vittorio Bertelè is a scholar working on Economics and Econometrics, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Vittorio Bertelè has authored 85 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Economics and Econometrics, 28 papers in Cardiology and Cardiovascular Medicine and 14 papers in Pharmacology. Recurrent topics in Vittorio Bertelè's work include Health Systems, Economic Evaluations, Quality of Life (31 papers), Antiplatelet Therapy and Cardiovascular Diseases (23 papers) and Pharmaceutical Economics and Policy (17 papers). Vittorio Bertelè is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (31 papers), Antiplatelet Therapy and Cardiovascular Diseases (23 papers) and Pharmaceutical Economics and Policy (17 papers). Vittorio Bertelè collaborates with scholars based in Italy, Denmark and France. Vittorio Bertelè's co-authors include Silvio Garattini, Roberta Joppi, Giovanni de Gaetano, Rita Banzi, Chiara Cerletti, E W Salzman, J. Anthony Ware, Ronald M. Weintraub, Robert L. Thurer and Joseph H. Troll and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Vittorio Bertelè

82 papers receiving 2.1k citations

Peers

Vittorio Bertelè

CCM

SURGE

PHARM

HEMAT

Craig J. Currie United Kingdom

Peter Henriksson Sweden

Kunitoshi Iseki Japan

J. Michael Gaziano United States

Arrigo Schieppati Italy

Patricia R. Hebert United States

Loes E. Visser Netherlands

Maria Carla Roncaglioni Italy

Sarah Parish United Kingdom

Hanna Mäenpää Finland

Craig J. Currie United Kingdom

Vittorio Bertelè

516 ×0.8

565 ×1.3

CCM

930 ×2.4

SURGE

222 ×0.9

PHARM

108 ×0.5

HEMAT

Citations per year, relative to Vittorio Bertelè Vittorio Bertelè (= 1×) peers Craig J. Currie

Countries citing papers authored by Vittorio Bertelè

Since Specialization

Citations

This map shows the geographic impact of Vittorio Bertelè's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vittorio Bertelè with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vittorio Bertelè more than expected).

Fields of papers citing papers by Vittorio Bertelè

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vittorio Bertelè. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vittorio Bertelè. The network helps show where Vittorio Bertelè may publish in the future.

Co-authorship network of co-authors of Vittorio Bertelè

This figure shows the co-authorship network connecting the top 25 collaborators of Vittorio Bertelè. A scholar is included among the top collaborators of Vittorio Bertelè based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vittorio Bertelè. Vittorio Bertelè is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Djurisic, Snezana, Ana Rath, Silvio Garattini, et al.. (2017). Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 18(1). 360–360. 103 indexed citations

Neugebauer, Edmund, Ana Rath, Michaela Eikermann, et al.. (2017). Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 18(1). 427–427. 67 indexed citations

Banzi, Rita, et al.. (2016). Older patients are still under-represented in clinical trials of Alzheimer’s disease. Alzheimer s Research & Therapy. 8(1). 32–32. 49 indexed citations

Garattini, Silvio, Vittorio Bertelè, & Guido Bertolini. (2013). A failed attempt at collaboration. BMJ. 347(sep04 1). f5354–f5354. 6 indexed citations

Garattini, Silvio & Vittorio Bertelè. (2009). Homoeopathy: not a matter for drug-regulatory authorities. The Lancet. 374(9701). 1578–1580. 4 indexed citations

Garattini, Silvio & Vittorio Bertelè. (2008). Do we learn the right things from clinical trials?. European Journal of Clinical Pharmacology. 64(2). 115–125. 2 indexed citations

Garattini, Silvio & Vittorio Bertelè. (2007). Non-inferiority trials are unethical because they disregard patients' interests. The Lancet. 370(9602). 1875–1877. 118 indexed citations

Garattini, Silvio & Vittorio Bertelè. (2007). How can we regulate medicines better?. BMJ. 335(7624). 803–805. 39 indexed citations

Joppi, Roberta, Vittorio Bertelè, & Silvio Garattini. (2006). Orphan drug development is progressing too slowly. British Journal of Clinical Pharmacology. 61(3). 355–360. 51 indexed citations

10.

Apolone, Giovanni, Roberta Joppi, Vittorio Bertelè, & Silvio Garattini. (2005). Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer. 93(5). 504–509. 84 indexed citations

11.

Garattini, Silvio & Vittorio Bertelè. (2003). Efficacy, safety and cost of new drugs acting on the central nervous system. European Journal of Clinical Pharmacology. 59(1). 79–84. 10 indexed citations

12.

Garattini, Silvio, et al.. (2003). European Council waters down European Parliament's drug-regulatory legislation. The Lancet. 362(9397). 1688–1689. 2 indexed citations

13.

Garattini, Silvio & Vittorio Bertelè. (2003). Efficacy, safety and cost of new cardiovascular drugs: a survey. European Journal of Clinical Pharmacology. 59(8-9). 701–706. 11 indexed citations

14.

Garattini, Silvio & Vittorio Bertelè. (2001). Adjusting Europe's drug regulation to public health needs. The Lancet. 358(9275). 64–67. 38 indexed citations

15.

Garattini, Silvio & Vittorio Bertelè. (2000). Policing the European pharmaceutical market's priorities. European Journal of Clinical Pharmacology. 56(5). 441–443. 2 indexed citations

16.

Bertelè, Vittorio. (1999). Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Annals of Internal Medicine. 130(5). 412–421. 32 indexed citations

17.

Bertelè, Vittorio, Maria Carla Roncaglioni, & Gianni Tognoni. (1996). Rationale and methodology of the I.C.A.I. study, a randomised clinical trial of alprostadil in the treatment of chronic critical leg ischemia. Journal of Nephrology. 9(2). 93–98. 2 indexed citations

18.

Bertelè, Vittorio, Chiara Cerletti, & Giovanni de Gaetano. (1992). Pathophysiology of Critical Leg Ischaemia and Mode of Action of Prostaglandins. Birkhäuser Basel eBooks. 37. 18–26.

19.

Libretti, A & Vittorio Bertelè. (1989). Antiplatelet Drugs in Secondary Prevention of Myocardial Infarction. Journal of Cardiovascular Pharmacology. 14. S89–S91. 2 indexed citations

20.

Cerletti, Chiara, et al.. (1987). Response of human platelets exposed to arachidonate upon stimulation with other agonists: Possible role of Ca2+i movement. Biochemical and Biophysical Research Communications. 149(3). 1193–1199. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact